European Journal of Obstetrics & Gynecology and Reproductive Biology
Clinical management of breast cancer in males: a report of four cases
Introduction
Breast cancer is a rare event in men, accounting for less then 1% of all breast cancers in both genders [1]. The incidence in Germany is documented at about 1.0 per year/100,000 (cancer registry of the county Saarland). In the US, only 0.2% of all malignancies in men account for this disease [8]. The first case of male breast cancer was reported by a British physician, John of Arderne, in the early 14th century [9].
The mean age at diagnosis is approximately 65 years. Although men of all ages can be affected by the disease, it is rare in young men. Radiation exposure, estrogen administration, and diseases associated with hyperestrogenism, such as liver cirrhosis or Klinefelter syndrome appear to be predisposing risk factors [2], [3], [4], [5]. There is an increased incidence of male breast cancer among men who have a number of female relatives with breast cancer. Furthermore, occurrence of male breast cancer increases the risk for breast cancer in predominantly first degree female relatives [35]. An increased risk of male breast cancer has been reported in families with a mutation in the breast cancer susceptibility gene BRCA-2, located on chromosome 13q [6], [7]. Male carriers of BRCA-mutations may act as conductors; they may not have an elevated risk for developing breast cancer, but they have a three-fold increased risk of suffering from colon or prostate cancer [10].
For a long time, it was generally been accepted that the prognosis of male breast cancer was worse than that of women suffering from breast cancer [9], [11], [13].
In the majority of patients, the first clinical symptom is a painless tumor in the breast, mostly detected by the patient himself. Discharge from the nipple as an early symptom of disease is reported in approximately 15% of all cases [9], [11]. Furthermore, some cases of inflammatory breast cancer in men have been reported [11]. As in women, the most important predictor of survival is the status of axillary lymphnodes involved. In 56% of invasive cancer a positive nodal status was found with significant correlation to primary tumor size [30]. Hereditary male breast cancer seems to have no different prognosis when compared at individual stages to their sporadic counterparts [12].
Section snippets
Patients and clinical management
From 1996 to 1999 four male patients with invasive breast cancer presented to our department and to the Department of Oncology at the Paracelsus Clinic of Osnabrueck. Patients’ characteristics including stage of disease at presentation, surgical management, lymph node involvement, histology and hormone receptor status, are listed in Table 1. Estrogen and progesterone receptor levels were evaluated by immunohistological staining using the Remmele score [36].
Case 1: A 57-year-old patient
Discussion
The first clinical sign of male breast cancer is often noted by the patient himself. In comparison to female breast cancer, the delay from onset of first clinical signs to diagnosis is approximately 22 months. This delay of diagnosis has severe impact on survival. Hill et al. demonstrated that patients with a delay of 6 months or less had a 5 and 10 years survival rate of 90 and 70%, respectively. On the other hand, patients with a duration of symptoms of more than 6 months had 5 and 10 years
Conclusions
To reduce the portion of advanced stages of the disease at diagnosis, measures should be taken to remind general practitioners and other healthcare providers of the entity of male breast cancer and to inform the public about the disease. In families with female breast cancer, breast examination in men should be performed and vice versa. In case of a male breast cancer, family members should be offered a genetic counseling for breast cancer risk evaluation and screening.
Currently, no clear data
References (50)
- et al.
Male breast cancer: results of the treatment and prognostic factors in 397 cases
Eur. J. Cancer
(1995) - et al.
Factors predicting delayed presentation of symptomatic breast cancer: a systematic review
Lancet
(1999) - et al.
Immunochistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) versus subjective grading (IRS)
Pathol. Res. Pract.
(1993) - et al.
Male breast cancer: clinicopathological features, immunocytochemical characteristics and prognosis
Eur. J. Surg. Oncol.
(1996) - et al.
Bcl-2 and P53 expression in node- negative breast carcinoma: a study with long term follow-up
Human Pathol.
(1996) - et al.
DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma
Hum. Pathol.
(1996) - et al.
Cancer statistics
Ca Cancer J. Clin.
(1997) - et al.
Male breast cancer: a 13-year review of 89 patients
J. Clin. Oncol.
(1984) - et al.
Carcinoma of the male breast
Ann. Intern. Med.
(1992) - et al.
Carcinoma of the male breast in association with the Klinefelter syndrome
Br. Med. J.
(1965)
Klinefelter syndrome and cancer: a family study
JAMA
XX male with breast cancer
Clin. Genet.
Breast carcinoma in a 46XX true hermaphrodite
Cancer
Male breast cancer: factors influencing prognosis
Br. J. Cancer
Germline BRCA-1 mutations in selected men with prostate cancer
Am. J. Genet.
Carcinoma of the male breast
Surg. Gynecol. Obstet.
Localized male breast carcinoma and family history
Cancer
Carcinoma of the male breast
Br. J. Surg.
Mutation analysis of BRCA-1 and BRCA-2 in male breast cancer population
Am. J. Hum. Genet.
BRCA-2 germline mutations are frequent in male breast cancer patients without a family history of the disease
Cancer Res.
Carcinoma of the breast in men
NY State J. Med.
Cancer of the male breast with prolonged survival
Cancer
Carcinoma of the male breast: analysis of prognosis compared with matched female patients
Ann. Surg. Oncol.
Mutations in the p53 gene in male breast cancer
Cancer
Cited by (17)
Male breast cancer: Similarities or differences with female breast cancer
2014, Feuillets de RadiologiePositive progesterone receptors and cell proliferation index: An independent association with breast cancer in males
2010, BreastCitation Excerpt :As compared to other series20,21 reporting lower values or even no differences, Ki-67 expression was significantly higher in male cancers in our study. High cell proliferation is a parameter related to malignant tumors with a poorer prognosis22 and a greater chance of causing distant disease,23,24 and has been suggested as a predictor of response to some primary chemotherapy regimens.25 Her2neu over-expression, an increasingly important factor in breast cancer management, has been described between 10% and 29% in male cases.26–28
Immunohistochemical expression in male breast cancer: Two case reports
2006, Kaohsiung Journal of Medical SciencesA pilot study to evaluate and explore the information and support offered to male breast cancer patients by breast care nurses
2006, Journal of Radiotherapy in PracticeAnalysis of male breast cancer patients: single center results
2021, Pamukkale Medical JournalSimultaneous beating heart coronary artery bypass surgery and modified radical mastectomy
2013, Heart Surgery Forum
- 1
Both authors contributed equally to the manuscript.